<DOC>
	<DOCNO>NCT00019071</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness cladribine follow radiation therapy treat patient malignant glioma .</brief_summary>
	<brief_title>Chemotherapy Followed Radiation Therapy Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose cladribine combination radiotherapy patient high grade glioma . II . Assess regimen term toxicity survival patient . III . Assess acute neurotoxicity continuous infusion cladribine patient . IV . Assess regimen term response , local control , time progression patient . V. Define dose level cladribine associate potentiation acute and/or delay radiation toxicity ( radiosensitizing dose level ) . OUTLINE : This dose escalation study cladribine . Patients receive cladribine continuous IV infusion 5 day week 4 week undergo radiotherapy twice day , begin 3 hour initiation cladribine , 5 day week 4.5 week . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos cladribine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow 1 month , every 3 month thereafter survival . PROJECTED ACCRUAL : A total 12-42 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven highgrade glioma confine 1 hemisphere brain include : Grade III astrocytoma ( anaplastic astrocytoma ) Grade IV astrocytoma ( glioblastoma multiforme ) ineligible NCI95C0069 protocol Histologic confirmation highgrade astrocytoma NIH neuropathology division require ( include mandatory review slide biopsy resection ) No evidence metastatic leptomeningeal spread PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % ECOG 02 Life expectancy : Greater 6 month Hematopoietic : WBC least 3,500/mm3 Absolute granulocyte count least 900/mm3 Absolute leukocyte count least 900/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Liver function test great 2.5 time upper limit normal Renal : Creatinine clearance least 95 mL/min Creatinine great 1.3 mg/dL Other : No history psychiatric disease would prevent compliance No malignancy within past 5 year except : Basal cell carcinoma skin Carcinoma situ cervix Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior cranial radiotherapy Surgery : No 3 month since surgery ( biopsy ; subtotal neartotal resection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>